Stock Scorecard



Stock Summary for Moderna Inc (MRNA) - $36.94 as of 11/20/2024 8:27:28 PM EST

Total Score

11 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MRNA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MRNA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MRNA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MRNA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MRNA (47 out of 90)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 8
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0

Latest News for for MRNA

Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines? - Moderna ( NASDAQ:MRNA ) , GSK ( NYSE:GSK ) 11/20/2024 1:41:00 PM
Unpacking the Latest Options Trading Trends in Moderna - Moderna ( NASDAQ:MRNA ) 11/19/2024 8:15:00 PM
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Metagenomi, Inc. ( MGX ) - Metagenomi ( NASDAQ:MGX ) 11/19/2024 6:33:00 PM
MGX DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action - MGX - Metagenomi ( NASDAQ:MGX ) 11/19/2024 6:27:00 PM
E-Prescribing Market Size to Surpass USD 13.93 Billion by 2031 | SkyQuest Technology 11/19/2024 9:10:00 AM
METAGENOMI ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Metagenomi, Inc. and Encourages Investors to Contact the Firm - Metagenomi ( NASDAQ:MGX ) 11/19/2024 2:00:00 AM
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi - Metagenomi ( NASDAQ:MGX ) 11/19/2024 1:23:00 AM
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination - Moderna ( NASDAQ:MRNA ) 11/18/2024 6:24:00 PM
Levi & Korsinsky Notifies Shareholders of Metagenomi, Inc. ( MGX ) of a Class Action Lawsuit and an Upcoming Deadline - Metagenomi ( NASDAQ:MGX ) 11/18/2024 6:16:00 PM
METAGENOMI ( NASDAQ: MGX ) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by November 25, 2024 - Metagenomi ( NASDAQ:MGX ) 11/18/2024 2:36:00 PM

Financial Details for MRNA

Company Overview

Ticker MRNA
Company Name Moderna Inc
Country USA
Description Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 36.94
Price 4 Years Ago 104.47
Last Day Price Updated 11/20/2024 8:27:28 PM EST
Last Day Volume 7,295,775
Average Daily Volume 7,376,584
52-Week High 170.47
52-Week Low 35.80
Last Price to 52 Week Low 3.18%

Valuation Measures

Trailing PE N/A
Industry PE 120.49
Sector PE 40.32
5-Year Average PE -10.88
Free Cash Flow Ratio 2.07
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 4.39
Total Cash Per Share 17.84
Book Value Per Share Most Recent Quarter 30.98
Price to Book Ratio 1.19
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 2.99
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 384,818,000
Market Capitalization 14,215,176,920
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -85.10%
Annual Earnings Growth -156.37%
Reported EPS 12 Trailing Months -5.81
Reported EPS Past Year -6.37
Reported EPS Prior Year -12.41
Net Income Twelve Trailing Months -2,224,000,000
Net Income Past Year -4,714,000,000
Net Income Prior Year 8,362,000,000
Quarterly Revenue Growth YOY 1.70%
5-Year Revenue Growth 118.81%
Operating Margin Twelve Trailing Months -0.04

Balance Sheet

Total Cash Most Recent Quarter 6,867,000,000
Total Cash Past Year 8,604,000,000
Total Cash Prior Year 9,902,000,000
Net Cash Position Most Recent Quarter 6,867,000,000
Net Cash Position Past Year 8,604,000,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 13,854,000,000
Total Stockholder Equity Prior Year 19,123,000,000
Total Stockholder Equity Most Recent Quarter 11,927,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -3,956,000,000
Free Cash Flow Per Share Twelve Trailing Months -10.28
Free Cash Flow Past Year -3,825,000,000
Free Cash Flow Prior Year 4,581,000,000

Options

Put/Call Ratio 0.74
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -4.47
MACD Signal -3.72
20-Day Bollinger Lower Band 26.40
20-Day Bollinger Middle Band 77.04
20-Day Bollinger Upper Band 127.68
Beta 1.69
RSI 24.60
50-Day SMA 97.52
150-Day SMA 127.78
200-Day SMA 158.22

System

Modified 11/19/2024 7:17:27 AM EST